It’s been two years since disappointing clinical trial results raised questions of whether Bluebird Bio (BLUE) was capable of developing a one-shot gene therapy cure for sickle cell disease. On Wednesday, the biotech disclosed the first preliminary data suggesting a significant obstacle may have been cleared.

The new data show that Bluebird has been able to increase the number of gene-corrected cells taking hold in the bone marrow of sickle cell patients by improving the manufacturing process for its gene therapy, known as LentiGlobin. That suggests the patients may be able to produce more normal red blood cells, rather than damaged, sickled cells.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy